GLP-1Ra in the treatment of Type 2 Diabetes Mellitus: An overview of systematic reviews

Keywords

Diabetes Mellitus
Type 2 (MeSH)
Glucagon-Like peptide-1(MeSH)
Cardiovascular Risk Factor (MeSH)
Renal Insufficiency (MeSH)
Hypoglycemia (MeSH)

How to Cite

Cantor Cruz, F., Gomez-Gomez, O., Mendivelso Duarte, F., Ruiz, P. C., Rincon Sierra, O., Yama Mosquera, E., Moscoso Martinez, E., Bohorquez, L. F., Gonzalez, C., Acevedo, J. R., Espitia Malagon, R. A., Pinto Pinzón, D., & Yomayusa Gonzalez, N. (2022). GLP-1Ra in the treatment of Type 2 Diabetes Mellitus: An overview of systematic reviews. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 9(2). https://doi.org/10.53853/encr.9.2.601

Abstract

Introduction: Diabetes mellitus is a serious chronic disease with a worldwide prevalence of 8.5% in people over 18 years of age, of which 90% belong to type 2; A pharmacological option for its management is GLP-1Ra, which has an efficacy in reducing glycosylated hemoglobin (HbA1c) of 0.9 to 1.6%.

Aim: To synthesize the evidence from systematic reviews on the safety of GLP-1Ra for cardiovascular and renal outcomes compared with standard therapy in adult patients with T2DM and the reported effectiveness. Methods: A comprehensive and systematic literature search was performed on Medline and Ovid with complementary search methods. Data selection and extraction was independent and paired. The methodological quality was evaluated with SING. The following were evaluated as intervention: Liraglutide, Lixisenatide, Albiglutide, Semaglutide, Dulaglutide, Exenatide, Taspoglutide and Efpeglenatide compared with placebo or active therapy.

Results: Seventeen studies were included, which grouped 47 unique clinical trials. The results show a trend in the protective effect for cardiovascular and renal outcomes, but very few analyses show to be statistically significant when the molecules are analyzed individually, also reporting contradictions in the direction of the effect for some cardiovascular outcomes.

Conclusions: The results should be interpreted with caution given the variability and contradiction in the direction of the effect in some cases. We suggest to decide their use in clinical practice according to the baseline characteristics of the patients and the individual safety results of each molecule.

https://doi.org/10.53853/encr.9.2.601

References

World Health Organization. Diabetes [Internet]. Ginebra: who.int; 2019. [citado el 01 de junio de 2019]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/diabetes

International Diabetes Federation. IDF DIABETES ATLAS Eighth edition 2017. Bruselas: diabetesatlas.org; 2017. [citado el 09 de octubre de 2019]. Disponible en: https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf

Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88-98. doi: 10.1038/nrendo.2017.151.

Organización mundial de la salud. Informe mundial sobre la diabetes. [Internet]. Ginebra: who.int;2016 [Citado el 01 de octubre de 2019]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/254649/9789243565255-spa.pdf;jsessionid=9D796A21E9C860C45911F5B34B58BF92?sequence=1

Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2 Diabetes: A Global Systematic Review. Pharmacoeconomics. 2015;33(8):811-31. doi: 10.1007/s40273-015-0268-9.

Babenko AY, Savitskaya DA, Kononova YA, Trofimova AY, Simanenkova AV, Vasilyeva EY, Shlyakhto EV. Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity. J Diabetes Res. 2019:1365162. doi: 10.1155/2019/1365162.

Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20(1):189. doi:10.1186/s12933-021-01366-8

Karagiannis T, Tsapas A, Athanasiadou E, Avgerinos I, Liakos A, Matthews DR, Bekiari E. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2021;174:108737. doi: 10.1016/j.diabres.2021.108737.

Ghosh-Swaby OR, Goodman SG, Leiter LA, Cheng A, Connelly KA, Fitchett D, Jüni P, Farkouh ME, Udell JA. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2020;8(5):418-435. doi: 10.1016/S2213-8587(20)30038-3.

Malhotra K, Katsanos AH, Lambadiari V, Goyal N, Palaiodimou L, Kosmidou M, Krogias C, Alexandrov AV, Tsivgoulis G. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. J Neurol. 2020;267(7):2117-2122. doi: 10.1007/s00415-020-09813-4.

Kristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Køber L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776-785. doi: 10.1016/S2213-8587(19)30249-9. Epub 2019 Aug 14. Erratum in: Lancet Diabetes Endocrinol. 2020;8(3):e2.

Duan CM, Wan TF, Wang Y, Yang QW. Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(46):e17860. doi: 10.1097/MD.0000000000017860.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. Circulation. 2019;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.

Sinha B, Ghosal S. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract. 2019;150:8-16. doi: 10.1016/j.diabres.2019.02.014

Al Yami MS, Alfayez OM, Alsheikh R. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. Heart Lung Circ. 2018;27(11):1301-1309. doi: 10.1016/j.hlc.2018.03.018.

Luo Y, Lu K, Liu G, Wang J, Laurent I, Zhou X. The Effects of Novel Antidiabetic Drugs on Albuminuria in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clin Drug Investig. 2018;38(12):1089-1108. doi: 10.1007/s40261-018-0707-4.

Zhang X, Shao F, Zhu L, Ze Y, Zhu D, Bi Y. Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis. BMC Pharmacol Toxicol. 2018;19(1):58. doi: 10.1186/s40360-018-0246-x.

Wang Q, Liu L, Gao L, Li Q. Cardiovascular safety of GLP-1 receptor agonists for diabetes patients with high cardiovascular risk: A meta-analysis of cardiovascular outcomes trials. Diabetes Res Clin Pract. 2018;143:34-42. doi: 10.1016/j.diabres.2018.06.009.

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6.

Gargiulo P, Savarese G, D'Amore C, De Martino F, Lund LH, Marsico F, Dellegrottaglie S, Marciano C, Trimarco B, Perrone-Filardi P. Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. Nutr Metab Cardiovasc Dis. 2017;27(12):1081-1088. doi: 10.1016/j.numecd.2017.09.006.

Li L, Li S, Liu J, Deng K, Busse JW, Vandvik PO, Wong E, Sohani ZN, Bala MM, Rios LP, Malaga G, Ebrahim S, Shen J, Zhang L, Zhao P, Chen Q, Wang Y, Guyatt GH, Sun X. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMC Cardiovasc Disord. 2016;16:91. doi: 10.1186/s12872-016-0260-0.

Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):740-51. doi: 10.7326/M15-2650.

Wang T, Wang F, Zhou J, Tang H, Giovenale S. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Diabetes Metab Res Rev. 2016;32(8):843-857. doi: 10.1002/dmrr.2804.

Perel C. Insuficiencia cardíaca y diabetes nuevos tratamientos para la diabetes. Insuf Card 2018;13(4):155-169

Villegas I. ¿Qué tan útiles en la práctica diaria para los nefrólogos son los nuevos antidiabéticos con protección cardiovascular? Rev. colom. nefrol. 2017; 4(1) http://dx.doi.org/10.22265/acnef.4.1.265

Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Nefrologia (Madr.) 2014; 34(1):0-138 DOI: 10.3265/Nefrologia.pre2013.Nov.12369

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2022 Revista Colombiana de Endocrinología, Diabetes & Metabolismo

Downloads

Download data is not yet available.